caa a22 4500 445338873 CHVBK 20180317142805.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1245/s10434-011-1768-2 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1768-2 Borrmann's Macroscopic Criteria and p-Smad2 Expression Are Useful Predictive Prognostic Markers for Cytology-Positive Gastric Cancer Patients Without Overt Peritoneal Metastasis [Elektronische Daten] [Satoru Noda, Masakazu Yashiro, Takahiro Toyokawa, Jyunya Morimoto, Osamu Shinto, Kazuya Muguruma, Tetsuji Sawada, Kosei Hirakawa] Background: All patients with peritoneal-free cancer cells (CY1) do not always develop a peritoneal recurrence (P1). The goal of this study was to identify characteristic features of peritoneal-free cancer cells that could develop into peritoneal recurrence. Methods: Of 1,474 patients, 91 were identified with CY1P0, and the remaining 1,383 with CY0P0. Immunohistochemical staining with anti-phosphorylated Smad 2 (p-Smad2) was performed on paraffin-embedded specimens from the 91 CY1P0 patients. Results: CY1 was significantly correlated with Borrmann's type-4 cancer, clinical T stage, and lymph node metastasis. CY1P0 patients with Borrmann's type-4 cancer more frequently develop peritoneal recurrence than do those with other types of tumors. The 5-year survival rate of patients with Borrmann's type-4 tumors was significantly (p=0.023) low (6.3%) compared with that of patients with other types of tumors (27.7%). The prognosis for p-Smad2-positive patients was significantly poorer than that of p-Smad2-negative patients. In CY1 and/or P1 patients with Borrmann's type-4 tumors, no significant difference in prognosis was identified between those who had surgery and those who did not. Conclusions: Activated Smad signaling might be associated with a high potential for peritoneal recurrence in CY1P0 patients. Borrmann's macroscopic criteria and p-Smad2 expression are useful markers for surgeons selecting advanced gastric cancer patients with CY1P0 for gastrectomy. Society of Surgical Oncology, 2011 Noda Satoru Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut Yashiro Masakazu Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut Toyokawa Takahiro Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut Morimoto Jyunya Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut Shinto Osamu Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut Muguruma Kazuya Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut Sawada Tetsuji Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut Hirakawa Kosei Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut Annals of Surgical Oncology Springer-Verlag 18/13(2011-12-01), 3718-3725 1068-9265 18:13<3718 2011 18 10434 https://doi.org/10.1245/s10434-011-1768-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1768-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Noda Satoru Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Yashiro Masakazu Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Toyokawa Takahiro Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Morimoto Jyunya Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Shinto Osamu Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Muguruma Kazuya Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Sawada Tetsuji Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut NATIONALLICENCE 700 1- Hirakawa Kosei Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/13(2011-12-01), 3718-3725 1068-9265 18:13<3718 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer